Plain-English translation of NCT07220993 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing CD7 CAR T cells, a new type of immune cell therapy made from your previous bone marrow donor's blood cells. Researchers will modify these cells in the lab to help them find and attack cancer cells, then give them back to you. You'll be followed for 15 years to make sure the treatment is safe and effective.
T-cell cancers are difficult to treat, especially when they return after a bone marrow transplant. This new treatment aims to harness your donor's immune cells to fight the cancer in a way that standard treatments have not been able to do.
You likely qualify if…
You likely don't qualify if…
First, your previous bone marrow donor will provide a blood sample from which the research team will create your modified immune cells in the lab. You will then receive two chemotherapy medications (cyclophosphamide and fludarabine) for 3 days each to prepare your body. After this, you will receive an infusion of the modified immune cells. You will have regular clinic visits to monitor how well the treatment is working and watch for any side effects, with follow-up care continuing for 15 years.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States